Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XJ101 Phase I Study in Healthy Subjects
NCT06014736Phase 1Active, not recruiting
- Sponsor
- Starmab
- Start
- Aug 2023
- Primary completion
- Mar 2024
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in Staphylococcus aureus infection comparing XJ101 with Placebo (2 arms). Primary endpoint: Any adverse events at 92 days. Started Aug 2023; status: active, not recruiting.
02
Drugs
XJ101
03
Conditions
Staphylococcus aureus infection
Beyond the preview
Go deeper on NCT06014736.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06014736.